Efficacy of pazufloxacin mesilate in Legionnaires’ disease: a case report and in vitro study of the isolate
Efficacy of pazufloxacin mesilate in Legionnaires’ disease: a case report and in vitro study of the isolate
复制标题
甲磺酸帕珠沙星治疗军团病的疗效：病例报告和分离株的体外研究
DOI：
--
复制
发表时间：
2005
影响因子：
2.2
通讯作者：
A. Saito
中科院分区：
文献类型：
--
作者：
F. Higa;T. Shinzato;Masato Toyama;Shusaku Haranaga;M. Furugen;M. Tateyama;K. Kawakami;A. Saito
我们在此报告一例经培养证实的退伍军人病用静脉注射甲磺酸帕珠沙星(PZFX)成功治疗的病例，PZFX是日本新批准的氟喹诺酮类药物。患者是一名51岁的男子，在被诊断为社区获得性肺炎后住院。从患者的支气管肺泡灌洗液(BAL)中分离到嗜肺军团菌SG1，并在BAL液中检测到该菌的可溶性抗原。随后，静脉注射PZFX一周，证明疗效显著。体外研究证实，PZFX对患者分离株具有良好的细胞外和细胞内活性。这一案例表明，PZFX是治疗退伍军人病的一种选择。
We report here a case of culture-proven Legionnaires’ disease successfully treated with intravenous injection of pazufloxacin mesilate (PZFX), a fluoroquinolone newly approved in Japan. The patient was a 51-year-old man hospitalized after a diagnosis of community-acquired pneumonia. Legionella pneumophila SG1 was isolated from the patient’s bronchoalveolar lavage (BAL) fluid, and the soluble antigen of the bacterium was detected in the fluid as well. Subsequently, intravenous PZFX was administered for a week and proved markedly effective. An in vitro study confirmed that PZFX had excellent extracellular and intracellular activity against the isolate from the patient. This case suggests that PZFX is an option for treating Legionnaires’ disease.